Menu
Oncology Evolved
Engineering the Next Generation of Off-the-Shelf Cell Therapies
PIPELINE
PRE-CLINICAL
CLINICAL
Partner
CAR-T (Off-the-Shelf)
T-ALL/LBL
WU-CART-007
Memory NK (1:1)
AML
WU-NK-101
AML
WU-NK-101 Asia (China, HK, Macao, Taiwan & Singapore)
Memory NK (Off-the-Shelf)
AML
WU-NK-101
Solid Tumors
WU-NK-101 + mAb
Solid Tumors
WU-NK-201 Engineered
LATEST NEWS
Wugen Receives U.S. FDA Fast Track and Rare Pediatric Disease Designations for WU-CART-007 for the Treatment of R/R T-ALL/LBL
ST. LOUIS, MO and SAN DIEGO, CA, July 19, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of…
Wugen Presents New Preclinical Data Demonstrating Enhanced Anti-Tumor Activity of WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress
-- WU-NK-101 exhibited enhanced metabolic flexibility and resistance to tumor microenvironment immunosuppression relative to conventional natural killer (NK) cells --…
Wugen to Participate in Upcoming June Investor Conferences
ST. LOUIS, MO and SAN DIEGO, CA, June 1, 2022- Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf…
Copyright © 2022 Wugen. All Rights Reserved.
a COGNEO design